MX2009004295A - Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa. - Google Patents

Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.

Info

Publication number
MX2009004295A
MX2009004295A MX2009004295A MX2009004295A MX2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A
Authority
MX
Mexico
Prior art keywords
prepare
pharmaceutical composition
indazolemethoxyalkanoic
acid
indazolemethoxyalkanoic acid
Prior art date
Application number
MX2009004295A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2009004295A publication Critical patent/MX2009004295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)

Abstract

Uso de un compuesto de fórmula (I) en donde R, R' y R'' tienen los significados dados en la descripción, opcionalmente en la forma de una sal del mismo con una base orgánica o mineral farmacéuticamente aceptable, para preparar una composición farmacéutica para reducir los niveles de triglicérido, colesterol y glucosa en sangre.
MX2009004295A 2006-11-24 2007-11-13 Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa. MX2009004295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (1)

Publication Number Publication Date
MX2009004295A true MX2009004295A (es) 2009-05-05

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004295A MX2009004295A (es) 2006-11-24 2007-11-13 Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.

Country Status (24)

Country Link
US (2) US8198310B2 (es)
EP (2) EP2409698B1 (es)
JP (1) JP5192490B2 (es)
KR (1) KR101413616B1 (es)
CN (1) CN101541323B (es)
AR (1) AR063894A1 (es)
AU (1) AU2007323351B2 (es)
BR (1) BRPI0718522A2 (es)
CA (1) CA2666371C (es)
CY (1) CY1116664T1 (es)
DK (2) DK2409698T3 (es)
EA (1) EA016885B1 (es)
ES (2) ES2403584T3 (es)
GE (1) GEP20125570B (es)
HK (2) HK1129071A1 (es)
IL (1) IL198286A (es)
IT (1) ITMI20062254A1 (es)
MX (1) MX2009004295A (es)
PL (2) PL2409698T3 (es)
PT (2) PT2409698E (es)
SG (1) SG176508A1 (es)
SI (2) SI2409698T1 (es)
UA (1) UA97123C2 (es)
WO (1) WO2008061671A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2462119B1 (en) 2009-08-03 2014-06-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required Magnesium intermediates
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2789849T3 (es) * 2014-05-15 2020-10-26 Translatum Medicus Inc Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2006117316A1 (en) * 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity
EP1959982B1 (en) * 2005-12-01 2012-08-08 Flinders Technologies PTY. Ltd. Methods and compositions for preventing and/or treating pancreatitis
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Also Published As

Publication number Publication date
ES2530623T3 (es) 2015-03-04
US20100069456A1 (en) 2010-03-18
PL2097080T3 (pl) 2013-07-31
CY1116664T1 (el) 2017-03-15
SG176508A1 (en) 2011-12-29
CA2666371A1 (en) 2008-05-29
EA200970506A1 (ru) 2009-10-30
BRPI0718522A2 (pt) 2013-11-12
CA2666371C (en) 2014-05-06
SI2409698T1 (sl) 2015-04-30
PT2409698E (pt) 2015-02-10
CN101541323A (zh) 2009-09-23
IL198286A (en) 2016-03-31
PT2097080E (pt) 2013-04-01
EP2409698B1 (en) 2015-01-21
EA016885B1 (ru) 2012-08-30
HK1165275A1 (en) 2012-10-05
AR063894A1 (es) 2009-02-25
CN101541323B (zh) 2012-01-04
DK2097080T3 (da) 2013-05-21
SI2097080T1 (sl) 2013-05-31
DK2409698T3 (en) 2015-04-27
AU2007323351A1 (en) 2008-05-29
UA97123C2 (uk) 2012-01-10
PL2409698T3 (pl) 2015-06-30
ES2403584T3 (es) 2013-05-20
US20120283307A1 (en) 2012-11-08
AU2007323351B2 (en) 2013-05-02
IL198286A0 (en) 2010-02-17
JP5192490B2 (ja) 2013-05-08
KR20090081410A (ko) 2009-07-28
US8846745B2 (en) 2014-09-30
HK1129071A1 (en) 2009-11-20
JP2010510263A (ja) 2010-04-02
GEP20125570B (en) 2012-07-10
EP2097080B1 (en) 2013-02-20
EP2409698A1 (en) 2012-01-25
WO2008061671A3 (en) 2008-11-27
WO2008061671A2 (en) 2008-05-29
US8198310B2 (en) 2012-06-12
ITMI20062254A1 (it) 2008-05-25
EP2097080A2 (en) 2009-09-09
KR101413616B1 (ko) 2014-07-01

Similar Documents

Publication Publication Date Title
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007135527A3 (en) Benzimidazolyl compounds
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MX2011012122A (es) Derivados de tiofeno.
TW200833663A (en) Therapeutic agents
IL213613A (en) History of pirazine, preparations containing them and their uses
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2009003169A (es) Derivados de sulfonamida.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
TW200800993A (en) Organic compounds
MX2009013003A (es) Derivados de piperidina-amida.

Legal Events

Date Code Title Description
FG Grant or registration